

An improved sample size calculation method for score tests in generalized linear models

Yongqiang Tang *

Tesaro, 1000 Winter St, Waltham, MA 02451

Liang Zhu

The University of Texas Health Science Center at Houston, Houston, TX 77030

Jiezhun Gu

Duke Clinical Research Institute, Durham, NC 27705

June 24, 2020

Abstract

Self and Mauritsen (1988) developed a sample size determination procedure for score tests in generalized linear models under contiguous alternatives. Its performance may deteriorate when the effect size is large. We propose a modification of the Self-Mauritsen method by taking into account of the variance of the score statistic under both the null and alternative hypotheses, and extend the method to noninferiority trials. The modified approach is employed to calculate the sample size for the logistic regression and negative binomial regression in superiority and noninferiority trials. We further explain why the formulae recently derived by Zhu and Lakkis tend to underestimate the required sample size for the negative binomial regression. Numerical examples are used to demonstrate the accuracy of the proposed method.

Keywords: Exemplary dataset; Negative binomial regression; Noninferiority trials; Power and sample size; Score confidence interval

*email: yongqiang_tang@yahoo.com

1 Introduction

Generalized linear models (GLM) have been commonly used in the analysis of biomedical data (Nelder and Wedderburn, 1972; McCullagh and Nelder, 1989). Statistical inference in GLMs is often based on the Wald test and the likelihood ratio (LR) test. However, the Wald and LR tests can be liberal in small and moderate samples. In the comparison of two binary proportions, the Wald and LR methods can be anti-conservative under some parameter configurations even when the sample size reaches 200 (Laud and Dane, 2014) because the logistic regression overestimates the odds ratio in these studies (Nemes et al., 2009). Similar phenomenon is observed in the analysis of over-dispersed count data using the negative binomial (NB) regression (Aban et al., 2009). The score test has been recommended to control the type I error rate when the sample size is relatively small. In fact, many widely used methods such as Pearson’s chi-squared test, Cochran-Mantel-Haenszel test and Wilcoxon rank sum test are score tests from GLMs.

One concern about the score test is its lower power when compared to the Wald test. In fact, the score test can sometimes be more powerful than the Wald test. Xing et al. (2012) observed that the Wald test from the logistic regression may often miss rare disease-causal variants that can be identified by other asymptotic tests in large case-control association studies. Table 1 presents two scenarios for comparing two binomial proportions on the risk difference metric, in which the score test has higher power than the Wald test. The first scenario tests for superiority when the sample sizes are unbalanced in the two groups. In scenario 2, a noninferiority (NI) test is considered under balanced sample sizes. The results also evidence that it may sometimes be inappropriate to use the power calculation procedure developed for the Wald test to estimate the power of the score test, and vice versa. Technical details on the score test and the exact power calculation can be found in Farrington and Manning (1990) and Tang (2019).

Self and Mauritsen (1988) developed a power and sample size calculation procedure for the score test from GLMs under sequences of contiguous alternatives (Cox and Hinkley, 1974). This method generally works well for alternatives close to the null hypothesis. Its accuracy may degrade when the group sample sizes are unbalanced or when the effect size is large (Self et al., 1992). Self and Mauritsen’s approach approximates the variance of the

group size		true proportion		Hypothesis	exact power (%)		
n_1	n_0	p_1	p_0		score ^(a)	Wald ^(b)	Wald2 ^(b)
60	30	0.1	0.3	$H_0 : p_1 \geq p_0$ vs $H_1 : p_1 < p_0$	67.33	60.81	65.28
80	80	0.35	0.4	$H_0 : p_1 \geq p_0 + 0.15$ vs $H_1 : p_1 < p_0 + 0.15$	75.37	74.05	-

Table 1: Two scenarios with higher power in the score test than in the Wald test

(a) Score test defined in equation (3) of [Farrington and Manning \(1990\)](#)

(b) Wald ($Z = \frac{\hat{p}_1 - \hat{p}_0 - M_0}{\sqrt{\hat{p}_1(1-\hat{p}_1)/n_1 + \hat{p}_0(1-\hat{p}_0)/n_0}}$) and Wald2 ($Z = \frac{\log\{[\hat{p}_1/(1-\hat{p}_1)]/[\hat{p}_0/(1-\hat{p}_0)]\}}{\sqrt{[n_1\hat{p}_1(1-\hat{p}_1)]^{-1} + [n_0\hat{p}_0(1-\hat{p}_0)]^{-1}}}$) are the Wald tests from the binomial regression respectively with identity and logit link functions

score statistic under the null hypothesis by the variance under the alternative hypothesis. This assumption is asymptotically correct under contiguous alternatives, but unlikely to hold at alternatives that are not close to the null hypothesis ([Self and Mauritsen, 1988](#)).

We propose a modification of Self and Mauritsen’s procedure by taking into account of the variance of the score statistic under both the null and alternative hypotheses. It can greatly improve the performance of the method. For example, [Tang \(2011\)](#) obtained the sample size formula for Wilcoxon rank sum test for ordinal outcomes on basis of the asymptotic variance of the U statistic under both hypotheses, which shows improvements over the formulae derived under contiguous alternatives ([Whitehead, 1993](#); [Zhao et al., 2008](#)). Similar ideas were employed by [Farrington and Manning \(1990\)](#) in the comparison of binary proportions in NI trials. In these simple cases, the score test and its asymptotic distribution can be obtained analytically. In this paper, we consider more complex situations where the model contains some nuisance parameters. The score test has been commonly used in the superiority trials. It is less well known how to use the score method to analyze the NI trials. In Section 2, we explain how to conduct the NI tests in GLM based on the score method, and introduce the modified sample size procedure for both superiority and NI trials via the exemplary dataset approach.

The proposed method is employed to estimate the sample size for the score test from the NB regression in Section 3, and for the score test from the logistic regression with categorical covariates in Section 4. The performance of the proposed method is assessed by numerical examples and compared with some existing procedures.

2 Score tests in GLM

2.1 Score test and score confidence interval

In GLMs, the scalar response variables y_1, \dots, y_n are assumed to have probability density functions of the form (Nelder and Wedderburn, 1972; McCullagh and Nelder, 1989)

$$f(y_i|x_i, \mathbf{z}_i, \beta, \boldsymbol{\alpha}, \phi) = \exp \left[\frac{y_i \theta_i - b(\theta_i)}{a(\phi)} + c(y_i, \phi) \right], \quad (1)$$

where θ_i is the canonical parameter and ϕ is the dispersion parameter. The mean of y_i is $\mu_i = \frac{\partial b(\theta_i)}{\partial \theta_i}$, and its variance is $V_i = \frac{\partial \mu_i}{\partial \theta_i} a(\phi)$. We assume that the covariates are related to the mean μ_i via a link function $\eta_i = \beta x_i + \boldsymbol{\alpha}' \mathbf{z}_i = g(\mu_i)$, where x_i is a scalar covariate, the vector \mathbf{z}_i contains other covariates including the intercept, and $(\beta, \boldsymbol{\alpha})$ are the regression coefficients. In the analysis of clinical trials, $x_i = 0$ or 1 is the treatment status.

Suppose we are interested in testing the hypothesis

$$H_0 : \beta = \beta_0 \text{ vs } H_1 : \beta \neq \beta_0.$$

Let $\begin{bmatrix} S_{\beta_n}(\beta, \boldsymbol{\lambda}) \\ S_{\boldsymbol{\lambda}_n}(\beta, \boldsymbol{\lambda}) \end{bmatrix} = \begin{bmatrix} \sum_{i=1}^n \frac{\partial \log[f(y_i|x_i, \mathbf{z}_i, \beta, \boldsymbol{\lambda})]}{\partial \beta} \\ \sum_{i=1}^n \frac{\partial \log[f(y_i|x_i, \mathbf{z}_i, \beta, \boldsymbol{\lambda})]}{\partial \boldsymbol{\lambda}} \end{bmatrix}$ be the score function, and

$I_n(\beta, \boldsymbol{\lambda}) = \begin{bmatrix} I_{\beta\beta_n}(\beta, \boldsymbol{\lambda}) & I'_{\beta\boldsymbol{\lambda}_n}(\beta, \boldsymbol{\lambda}) \\ I_{\beta\boldsymbol{\lambda}_n}(\beta, \boldsymbol{\lambda}) & I_{\boldsymbol{\lambda}\boldsymbol{\lambda}_n}(\beta, \boldsymbol{\lambda}) \end{bmatrix}$ the expected information matrix, where the subscript n refers to the sample size, and $\boldsymbol{\lambda} = (\boldsymbol{\alpha}', \phi)$ is the vector of nuisance parameters. Let $\hat{\boldsymbol{\lambda}} = (\hat{\boldsymbol{\alpha}}, \hat{\phi})$ be the maximum likelihood estimate (MLE) under the restriction of $\beta = \beta_0$. That is, $n^{-1} S_{\boldsymbol{\lambda}_n}(\beta_0, \hat{\boldsymbol{\lambda}}) = \mathbf{0}$.

The score statistic for testing $H_0 : \beta = \beta_0$ can be written as (Cox and Hinkley, 1974)

$$Z(\beta_0) = \frac{S_{\beta_n}(\beta_0, \hat{\boldsymbol{\lambda}})}{\sqrt{V_n}} = \frac{S_{\beta_n}(\beta_0, \hat{\boldsymbol{\lambda}})}{\sqrt{I_{\beta\beta_n}(\beta_0, \hat{\boldsymbol{\lambda}}) - I'_{\beta\boldsymbol{\lambda}_n}(\beta_0, \hat{\boldsymbol{\lambda}}) I_{\boldsymbol{\lambda}\boldsymbol{\lambda}_n}^{-1}(\beta_0, \hat{\boldsymbol{\lambda}}) I_{\beta\boldsymbol{\lambda}_n}(\beta_0, \hat{\boldsymbol{\lambda}})}. \quad (2)$$

The null hypothesis is rejected if $|Z(\beta_0)| \geq z_{1-\alpha/2}$, where z_p is the p th percentile of $N(0, 1)$.

As will be illustrated in Section 3, the score test can be used to test the hypothesis in superiority and NI trials by setting β_0 as the superiority and NI margin. The confidence

interval (CI) is often reported to quantify the uncertainty in the estimated effect. The $(1 - \alpha)100\%$ score CI for β can be obtained by inverting the score test

$$\{\beta : |Z(\beta)| \leq z_{1-\alpha/2}\}.$$

Statistical decision can be made equivalently based on the score CI. The null hypothesis is rejected if the score CI does not contain the null hypothesis value.

2.2 Asymptotic distribution of the score statistic

The score test and its asymptotic distribution usually have explicit analytic expressions in the simple two-group comparison if the model does not contain an unknown dispersion parameter. Please refer to [Farrington and Manning \(1990\)](#) and [Tang \(2019\)](#) for examples. We consider more general cases where the vector of nuisance parameters $\boldsymbol{\lambda}$ contains other parameters in addition to an intercept term.

In general, $\hat{\boldsymbol{\lambda}}$ is not a consistent estimate of $\boldsymbol{\lambda}$ under the restriction of $\beta = \beta_0$. It will converge to the limiting value $\boldsymbol{\lambda}^*$ defined as the solution to the following equation ([Self and Mauritsen, 1988](#))

$$\lim_{n \rightarrow \infty} E[n^{-1} S_{\lambda_n}(\beta_0, \hat{\boldsymbol{\lambda}})] = \mathbf{0}. \quad (3)$$

We estimate $\boldsymbol{\lambda}^*$ by adapting the method of [Lyles et al. \(2007\)](#). We firstly construct an exemplary dataset consisting of records for every possible combination of the covariates and outcomes. Each record has a weight that represents the frequency of the covariate and outcome in the population. A weighted regression is fitted to the exemplary dataset using the standard statistical software. We assume that all covariates are categorical. A continuous covariate can be discretized using a large number of categories. Suppose there are a finite number of distinct covariate configurations $\{(\mathbf{z}_k, x_k); k = 1, \dots, m\}$, and the proportion of each configuration is π_k in the population. Suppose the response variable takes J possible values (y_1, \dots, y_J) . We can estimate $\boldsymbol{\lambda}^*$ by fitting the null model to the following dataset with mJ observations, where $w_{kj} = \pi_k \Pr(Y = y_j | x_k, \mathbf{z}_k, \beta, \boldsymbol{\lambda})$ is the weight attached to each observation, and the total weight in all observations is $\sum_{i=1}^m \sum_{j=1}^J w_{ij} = 1$.

$$\begin{array}{cccc}
x_1 & z_1 & y_1 & w_{11} \\
\dots & & & \\
x_1 & z_1 & y_J & w_{1J} \\
\dots & & & \\
x_m & z_m & y_1 & w_{m1} \\
\dots & & & \\
x_m & z_m & y_J & w_{mJ}
\end{array}$$

Lyles et al. (2007) approach is slightly different. It requires a much larger dataset, and can only estimate the power at a given sample size. The total weight in Lyles et al. (2007) approach is equal to the total sample size N . Let's give a simple example of comparing two binary proportions with $\Pr(y = 1|x = 1) = 0.8$ and $\Pr(y = 1|x = 0) = 0.4$. Suppose $N = 100$, and 75% patients are assigned to the experimental arm ($x = 1$). Then $(m, J) = (2, 2)$. Our approach includes 4 observations: $(x = 1, y = 1, w = 0.6)$, $(x = 1, y = 0, w = 0.15)$, $(x = 0, y = 1, w = 0.1)$ and $(x = 0, y = 0, w = 0.15)$. In Lyles et al. (2007) approach, the dataset consists of 200 pseudo-observations with 75 copies of $(x = 1, y = 1, w = 0.8)$ and $(x = 1, y = 0, w = 0.2)$ for subjects in the experimental arm, and 25 copies of $(x = 0, y = 1, w = 0.4)$ and $(x = 0, y = 0, w = 0.6)$ for placebo subjects. If observations with the same (x, y) are combined by adding up their weights, the dataset in Lyles et al. (2007) approach becomes a dataset with four observations $(x = 1, y = 1, w = 60)$, $(x = 1, y = 0, w = 15)$, $(x = 0, y = 1, w = 10)$ and $(x = 0, y = 0, w = 15)$. The ratio of the weights for observations with the same (x, y) is $N : 1$ between Lyles et al. (2007) approach and our approach.

Our method is more convenient and potentially more accurate than Lyles et al. (2007) approach. In Lyles et al. (2007) method, one needs to guess the sample size, construct the exemplary dataset, fit the null model and estimate the power at the given sample size. The whole process needs to be repeated if the sample size changes. In theory, λ^* remains unchanged, and the noncentrality parameter of the Wald, Score or LR test or its square change proportionally if we increase or decrease the total sample size. Therefore, the power and sample size calculation can be implemented by first fitting the model at a fixed sample size, and then using analytic methods to adjust the noncentrality parameter and solve the power or sample size equations accordingly. We fit the null model using SAS Proc Genmod with the FREQ option to incorporate the weight. One shall not use the Weight option in

the Genmod procedure since it is used to adjust for the dispersion parameter. Because the Genmod procedure truncates the weight to an integer, we **multiply** all the weights by a large value (say 10^9) to minimize the effect of truncation. **Lyles et al. (2007)** fits the model at the sample size for the trial, which is typically small (i.e. below 1,000). The weight after truncation in **Lyles et al. (2007)** method may no longer represent the frequency of the covariate and outcome in the population, and the estimation of $\boldsymbol{\lambda}^*$ can be inaccurate.

In **Self and Mauritsen (1988)**, an exemplary dataset contains m records for all possible combinations of the covariates, where the weight is the frequency of the covariates, and the response outcome is the expected value of response at the covariate configuration. The data structure may not be acceptable by some statistical software packages, and does not allow the estimation of the dispersion parameter ϕ^* .

In GLMs, the inference is made by assuming the covariates are known and fixed, but the covariates are typically unobserved at the design stage of a clinical trial. For example, although gender is fixed for each patient, it will be treated as unknown at the design stage since we do not know which patients will be enrolled. We firstly derive the mean and variance of the score statistic given the covariates, which are then averaged over all possible combinations of the covariates.

Let $S^{(k)}(\beta, \boldsymbol{\lambda}) = \begin{bmatrix} S_{\beta}^{(k)}(\beta, \boldsymbol{\lambda}) \\ S_{\boldsymbol{\lambda}}^{(k)}(\beta, \boldsymbol{\lambda}) \end{bmatrix} = \begin{bmatrix} \frac{\partial \log[f(y_i|x_k, \mathbf{z}_k, \beta, \boldsymbol{\lambda})]}{\partial \beta} \\ \frac{\partial \log[f(y_i|x_k, \mathbf{z}_k, \beta, \boldsymbol{\lambda})]}{\partial \boldsymbol{\lambda}} \end{bmatrix}$ denote the contribution to the score function from a subject with covariate (x_k, \mathbf{z}_k) . Let $E^{(k)}$ and $V^{(k)}$ represent, respectively, the mean and variance of $S^{(k)}(\beta_0, \boldsymbol{\lambda}^*)$ under the true model (1). Let $E = (E_{\beta}, E_{\boldsymbol{\lambda}})' = \sum_{k=1}^m \pi_k E^{(k)}$ and $V = \sum_{k=1}^m \pi_k V^{(k)}$. Note that $E_{\boldsymbol{\lambda}} = \mathbf{0}$ by equation (3). The asymptotic distribution of $(S_{\beta_n}(\beta, \boldsymbol{\lambda}^*), S_{\boldsymbol{\lambda}_n}(\beta, \boldsymbol{\lambda}^*))'$ is given by

$$n^{1/2} \begin{bmatrix} n^{-1} S_{\beta_n}(\beta, \boldsymbol{\lambda}^*) - E_{\beta}, \\ n^{-1} S_{\boldsymbol{\lambda}_n}(\beta, \boldsymbol{\lambda}^*) - E_{\boldsymbol{\lambda}} \end{bmatrix} \sim N(0, V). \quad (4)$$

Let $\mathcal{J}^{(k)}(\beta, \boldsymbol{\lambda}) = - \begin{bmatrix} \frac{\partial^2 \log[f(y_i|x_k, \mathbf{z}_k, \beta, \boldsymbol{\lambda})]}{\partial \beta^2} & \frac{\partial^2 \log[f(y_i|x_k, \mathbf{z}_k, \beta, \boldsymbol{\lambda})]}{\partial \beta \partial \boldsymbol{\lambda}'} \\ \frac{\partial^2 \log[f(y_i|x_k, \mathbf{z}_k, \beta, \boldsymbol{\lambda})]}{\partial \beta \partial \boldsymbol{\lambda}} & \frac{\partial^2 \log[f(y_i|x_k, \mathbf{z}_k, \beta, \boldsymbol{\lambda})]}{\partial \boldsymbol{\lambda} \partial \boldsymbol{\lambda}'} \end{bmatrix}$ denote the contribution to the observed information matrix from a subject with covariate (x_k, \mathbf{z}_k) . Let $\tilde{I}^{(k)}(\beta_0, \boldsymbol{\lambda}^*)$ be

the expectation of $\mathcal{J}^{(k)}(\beta_0, \boldsymbol{\lambda}^*)$ under the true model (1), and $\tilde{I}(\beta_0, \boldsymbol{\lambda}^*) = \begin{bmatrix} \tilde{I}_{\beta\beta}(\beta_0, \boldsymbol{\lambda}^*) & \tilde{I}'_{\beta\lambda}(\beta_0, \boldsymbol{\lambda}^*) \\ \tilde{I}'_{\beta\lambda}(\beta_0, \boldsymbol{\lambda}^*) & \tilde{I}_{\lambda\lambda}(\beta_0, \boldsymbol{\lambda}^*) \end{bmatrix} = \sum_{k=1}^m \pi_k \tilde{I}^{(k)}(\beta_0, \boldsymbol{\lambda}^*)$. By the Taylor series expansion, we get

$$n^{-1/2} S_{\beta_n}(\beta_0, \hat{\boldsymbol{\lambda}}) \approx n^{-\frac{1}{2}} S_{\beta_n}(\beta_0, \boldsymbol{\lambda}^*) - \tilde{I}'_{\beta\gamma}(\beta_0, \boldsymbol{\gamma}^*) \tilde{I}_{\gamma\gamma}^{-1}(\beta_0, \boldsymbol{\gamma}^*) n^{-\frac{1}{2}} S_{\gamma_n}(\beta_0, \boldsymbol{\gamma}^*). \quad (5)$$

Combining equations (4) and (5) yields the asymptotic distribution of the score statistic

$$n^{\frac{1}{2}} [n^{-1} S_{\beta_n}(\beta_0, \hat{\boldsymbol{\lambda}}) - E_\beta] \sim N(0, \sigma_1^2), \quad (6)$$

where $\sigma_1^2 = AVA'$, $A = [1, -\tilde{I}'_{\beta\gamma}(\beta_0, \boldsymbol{\gamma}^*) \tilde{I}_{\gamma\gamma}^{-1}(\beta_0, \boldsymbol{\gamma}^*)]$. In the special case considered by [Self and Mauritsen \(1988\)](#), $\tilde{I}(\beta_0, \boldsymbol{\lambda}^*)$ is identical to the Fisher information matrix $I(\beta_0, \boldsymbol{\lambda}^*) = \begin{bmatrix} I_{\beta\beta}(\beta_0, \boldsymbol{\lambda}^*) & I'_{\beta\lambda}(\beta_0, \boldsymbol{\lambda}^*) \\ I_{\beta\lambda}(\beta_0, \boldsymbol{\lambda}^*) & I_{\lambda\lambda}(\beta_0, \boldsymbol{\lambda}^*) \end{bmatrix}$ for the exemplary dataset under H_0 , and therefore $A = [1, -I'_{\beta\gamma}(\beta_0, \boldsymbol{\gamma}^*) I_{\gamma\gamma}^{-1}(\beta_0, \boldsymbol{\gamma}^*)]$.

As $n \rightarrow \infty$, the null variance $n^{-1} V_n = n^{-1} [I_{\beta\beta_n}(\beta_0, \hat{\boldsymbol{\lambda}}) - I'_{\beta\lambda_n}(\beta_0, \hat{\boldsymbol{\lambda}}) I_{\lambda\lambda_n}^{-1}(\beta_0, \hat{\boldsymbol{\lambda}}) I_{\beta\lambda_n}(\beta_0, \hat{\boldsymbol{\lambda}})]$ converges in probability to

$$\sigma_0^2 = I_{\beta\beta}(\beta_0, \boldsymbol{\lambda}^*) - I'_{\beta\gamma}(\beta_0, \boldsymbol{\lambda}^*) I_{\lambda\lambda}^{-1}(\beta_0, \boldsymbol{\lambda}^*) I_{\beta\lambda}(\beta_0, \boldsymbol{\lambda}^*). \quad (7)$$

2.3 Power and Sample Size formulae

The power of the score test (2) is given by

$$P = \Phi \left(\frac{\sqrt{n} |E_\beta|}{\sqrt{\sigma_1^2}} - z_{1-\frac{\alpha}{2}} \sqrt{\frac{\sigma_0^2}{\sigma_1^2}} \right), \quad (8)$$

where $\Phi(\cdot)$ is the standard normal cumulative distribution function, and σ_0^2 and σ_1^2 are defined in equations (6) and (7). Inverting (8) yields the sample size

$$N_{new} = \frac{(z_{1-\alpha/2} \sigma_0 + z_P \sigma_1)^2}{E_\beta^2}. \quad (9)$$

[Self and Mauritsen \(1988\)](#) method is formulated on basis of the noncentral chi-squared distribution, and the power and sample size estimates can be well approximated by

$$\begin{aligned} P_{SM} &= \Phi \left(\frac{\sqrt{n}|E_\beta|}{\sqrt{\sigma_1^2}} - z_{1-\frac{\alpha}{2}} \right), \\ N_{SM} &= \frac{(z_{1-\alpha/2} + z_P)^2 \sigma_1^2}{E_\beta^2}. \end{aligned} \tag{10}$$

It assumes $\sigma_0^2 \approx \sigma_1^2$. The assumption holds under a sequence of contiguous alternatives. [Self et al. \(1992\)](#) showed that the performance of the [Self and Mauritsen \(1988\)](#) procedure may degrade when the effect size is large or when the group sample sizes are unbalanced.

It is generally easier to compute σ_0^2 than σ_1^2 . Under contiguous alternatives, the power and sample size can also be calculated as

$$\begin{aligned} P_{s0} &= \Phi \left(\frac{\sqrt{n}|E_\beta|}{\sqrt{\sigma_0^2}} - z_{1-\frac{\alpha}{2}} \right), \\ N_{s0} &= \frac{(z_{1-\alpha/2} + z_P)^2 \sigma_0^2}{E_\beta^2}. \end{aligned} \tag{11}$$

3 Sample size for NB regression

The NB regression has been widely used to analyze overdispersed count data and recurrent event data. The NB distribution can be written as a Poissongamma mixture. If Y follows a Poisson distribution with mean $\epsilon\mu$, where ϵ is gamma distributed with mean 1 and variance κ , the marginal distribution of Y is $NB(\mu, \kappa)$

$$\Pr(Y = y|\mu, \kappa) = \frac{\Gamma(y + 1/\kappa)}{y!\Gamma(1/\kappa)} \left[\frac{\kappa\mu}{1 + \kappa\mu} \right]^y \left[\frac{1}{1 + \kappa\mu} \right]^{1/\kappa}, \quad y = 0, 1, 2, \dots, \tag{12}$$

where $\Gamma(\cdot)$ is the Gamma function.

Suppose in a trial, n subjects are assigned randomly to either the experimental ($g = 1$) or control ($g = 0$) treatment group. Let n_g be the number of subjects in group g . We assume the planned treatment duration is τ_c for each subject, but subjects may discontinue the study with the loss-to-follow-up distribution $G(t)$. Let t_i be the follow-up time, and y_i the

number of events for subject i . Then $y_i|g_i = g, t_i \sim NB(\lambda_g t_i, \kappa)$, where λ_g is the event rate in group g .

Suppose a lower event rate indicates better health status. In a superiority trial, the purpose is to demonstrate that the experimental treatment can reduce the event rate relative to the control treatment. The hypothesis can be written as

$$H_0 : \frac{\lambda_1}{\lambda_0} = 1 \text{ vs } H_1 : \frac{\lambda_1}{\lambda_0} < 1. \quad (13)$$

In a NI trial, the objective (Tang, 2017, 2018b) is to show that the test treatment is not materially less efficacious than a standard control treatment by proving $\lambda_1/\lambda_0 < M_0$, where M_0 is the prespecified margin that is bigger than 1, but close to 1. The hypothesis can be written as

$$H_0 : \frac{\lambda_1}{\lambda_0} = M_0 \text{ vs } H_1 : \frac{\lambda_1}{\lambda_0} < M_0. \quad (14)$$

Mathematically, the superiority trial can be viewed as a special case of the NI trial by setting $M_0 = 1$.

Let $\beta = \log(\lambda_1/\lambda_0)$, $\beta_0 = \log(M_0)$ and $\alpha = \log(\lambda_0)$. Since $\mu_i = \alpha + \log(t_i) + g_i \log(M_0)$ under H_0 , the null model can be easily fitted using standard software packages (e.g. SAS Proc Genmod) by setting the offset as $\log(t_i)$ for subjects in the control group, and $\log(M_0 t_i)$ for subjects in the experimental arm. The score test can be written as

$$Z_s = \frac{\sum_{\{i:g_i=1\}} \frac{y_i - \hat{\mu}_i}{1 + \hat{\kappa} \hat{\mu}_i}}{\sqrt{\frac{\hat{d}_0 \hat{d}_1}{\hat{d}_0 + \hat{d}_1}}}, \quad (15)$$

where $\hat{\mu}_i = \exp(\hat{\alpha} + \beta_0 g_i) t_i$, and $\hat{d}_g = \sum_{\{i:g_i=g\}} \hat{\mu}_i / (1 + \hat{\kappa} \hat{\mu}_i)$ for $g = 0$ and 1 .

The power and sample size can be calculated using the procedure described in Section 2. The expressions for the score function, observed and expected information matrix are given in equations (2.3)-(2.8) in Lawless (1987). In our implementation, the continuous time to follow-up is approximated by a categorical variable with $L = 100$ levels

$$t = \begin{cases} t_L = \tau_c & \text{with probability } p_L = 1 - G(\tau_c) \\ t_l = G^{-1} \left(\frac{p_L(l-0.5)}{L-1} \right) & \text{with probability } (1 - p_L)/(L - 1) \text{ for } l = 1, \dots, L - 1. \end{cases} \quad (16)$$

The final result is insensitive to the choice of L if L is not too small. We allow the loss-to-follow-up distribution to differ by the treatment group. There are $m = 2L$ possible combinations of the values for the treatment and time to follow-up. We truncate the number of response categories at a large number $J = 200$ so that $\Pr(y_{ij} \geq J) < 10^{-5}$. The full exemplary dataset consists of mJ observations. The weights for the $mJ = 2LJ$ observations are calculated according to the treatment allocation ratio and the true distribution defined in equation (12). It requires the specification of the dispersion parameter κ and the event rates for each group. As mentioned in Section 2.2, we **multiply** all the weights by a large value (say 10^9) to minimize the effect of truncation since the SAS Genmod procedure truncates the weight to an integer.

When all subjects have equal follow-up time ($t_{gj} \equiv t$), the method can be slightly simplified with $m = 2$. In this paper, we focus on the analysis of recurrent events. The simplified procedure is also suitable for other types of overdispersed counts such as the number of magnetic resonance imaging lesions in multiple sclerosis trials. Let μ_g and \bar{y}_g be, respectively, the expected and observed mean count in group g . For recurrent events, $\mu_g = \lambda_g t$. The score test (15) reduces to

$$W_s = \frac{\bar{y}_1 - M_0 \bar{y}_0}{\sqrt{n_1^{-1}(\hat{\mu}_1 + \hat{\kappa} \hat{\mu}_1^2) + n_0^{-1}(\hat{\mu}_0 + \hat{\kappa} \hat{\mu}_0^2)}}, \quad (17)$$

where $\hat{\mu}_1 = M_0 \hat{\mu}_0$ is the MLE under H_0 . Test (17) is similar to the test (equation (7)) of **Farrington and Manning (1990)** for assessing the relative risk between two binomial proportions. In this special case, the sample size in the control arm is

$$n_0 = \frac{\left[z_{1-\alpha/2} \sqrt{\theta^{-1}(\mu_1^* + \kappa^* \mu_1^{*2}) + (\mu_0^* + \kappa^* \mu_0^{*2})} + z_P \sqrt{\theta^{-1}(\mu_1 + \kappa \mu_1^2) + (\mu_0 + \kappa \mu_0^2)} \right]^2}{(\mu_1 - M_0 \mu_0)^2}, \quad (18)$$

where $\theta = n_1/n_0$ and $(\mu_0^*, \mu_1^*, \kappa^*)$ can be estimated by the exemplary dataset method. In superiority trials, we can approximate $(\mu_0^*, \mu_1^*, \kappa^*)$ by the method of moments,

$$\mu_0^* = \mu_1^* = \bar{\mu} = \frac{\theta \mu_1 + \mu_0}{\theta + 1} \quad \text{and} \quad \kappa^* = \frac{\kappa(\theta \mu_1^2 + \mu_0^2)}{(\theta + 1)\bar{\mu}^2} + \frac{\theta(\mu_1 - \mu_0)^2}{(\theta + 1)^2 \bar{\mu}^2}, \quad (19)$$




Figure 1: Plot of the chi-square statistic ($Z^2(\beta)$ from the score test) as a function of M_0 in a CGD trial

where $\kappa^* > \kappa$ if $\mu_1 \neq \mu_0$, and κ^* is the solution to

$$n_1 \frac{E(y_1 - \mu_1^*)^2}{\mu_1^*(1 + \kappa^* \mu_1^*)} + n_0 \frac{E(y_0 - \mu_0^*)^2}{\mu_0^*(1 + \kappa^* \mu_0^*)} = n_1 + n_0.$$

It would be interesting to compare the proposed method with that recently developed by [Zhu and Lakkis \(2014\)](#) and [Zhu \(2017\)](#) for superiority and NI trials because they use a similar idea to the score test. The approaches of [Zhu and Lakkis \(2014\)](#) and [Zhu \(2017\)](#) are based on the statistic $\log(\hat{\mu}_1/\hat{\mu}_0) - \log(M_0)$ instead of the score statistic

$$n_0 = \frac{\left[z_{1-\alpha/2} \sqrt{\frac{1}{\mu_0^{**}} + \frac{1}{\theta \mu_1^{**}} + \frac{1+\theta}{\theta} \kappa} + z_P \sqrt{\frac{1}{\mu_0} + \frac{1}{\theta \mu_1} + \frac{1+\theta}{\theta} \kappa} \right]^2}{[\log(\mu_1/\mu_0) - \log(M_0)]^2}, \quad (20)$$

where κ is assumed to be known, $a = -\kappa M_0(1 + \theta)$, $b = \kappa(\mu_0 M_0 + \theta \mu_1) - (1 + \theta M_0)$, $c = \mu_0 + \theta \mu_1$, and $\mu_0^{**} = ([-b - \sqrt{b^2 - 4ac}]/2a)$ and $\mu_1^{**} = M_0 \mu_0^{**}$ are the limiting values of the restricted MLE at given κ . [Zhu and Lakkis \(2014\)](#) and [Zhu \(2017\)](#) implicitly make two approximations. Firstly, the follow-up time is set to their mean values (i.e. $t_i = \bar{t}$) for all individuals, leading to underestimated variance of $\log(\hat{\mu}_1/\hat{\mu}_0) - \log(M_0)$ under both H_0 and H_1 (this can be proved by using the inequality in Appendix A.2 of [Tang \(2015\)](#)). Secondly, it approximates κ^* by κ , and the null variance of $\log(\hat{\mu}_1/\hat{\mu}_0) - \log(M_0)$ is usually underestimated since κ^* obtained under the null hypothesis in the score approach tends to

be larger than κ particularly when the treatment effect is large. This is shown in equation (19) for superiority trials when all subjects have equal follow-up time. The phenomenon is analogous to the comparison of two groups with continuous outcomes, in which the variance estimate based on the pooled outcomes $y_{i0} \sim N(\mu_0, \sigma^2)$ and $y_{i1} \sim N(\mu_1, \sigma^2)$ tends to overestimate the true variance if the mean difference is ignored. Therefore Zhu-Lakkis’s approach tends to underestimate the sample size. In superiority trials ($M_0 = 1$) with equal treatment allocation, Zhu-Lakkis’s sample size estimate is strictly smaller than the lower sample size bound of Tang (2015) for the Wald test from the NB regression (Tang, 2017).

Below we present several examples to illustrate the proposed method.

Example 1 Chronic granulomatous disease (CGD) is a rare inherited disorder of the immune system, characterized by recurrent pyogenic infections. Suppose we plan to design a two-arm CGD trial to assess the effect of an experimental treatment on the infection rate. Some parameters are estimated from a CGD trial analyzed by Matsui (2005) and Tang (2018a). The historical trial enrolled $n = 128$ eligible patients. It was terminated early for efficacy based on an interim analysis. In the trial, 14 (22.2%) out of 63 patients in the gamma interferon group and 30 (46.2%) out of 65 patients on placebo had at least one serious infection. We analyze the number of repeated infections using the NB regression. The event rate ratio between two treatments based on the Wald statistic is 0.3566 (95% CI: [0.1934, 0.6575]). Figure 1 plots the chi-square statistic (i.e. $Z^2(\beta)$ from the score test) as a function of M_0 . The score CI is [0.1957, 0.6681], which corresponds to the region $\{\beta : Z^2(\beta) \leq z_{1-\alpha/2}^2 = 3.814\}$. The score CI is slightly wider than the Wald CI.

We estimate the sample size at the following parameter values. The infection rate is $\lambda_0 = 1.1$ infections per year in the control arm, and $\kappa = 0.9$, which are close to the unconstrained MLE ($\hat{\lambda}_0 = 1.07$, $\hat{\kappa} = 0.91$) from the analysis of the historical CGD trial. Suppose the experimental treatment can reduce the infection rate by 60% (i.e. $\lambda_1/\lambda_0 = 0.4$). The target power is 80% or 90%, and the two-sided significance level is $\alpha = 0.05$. The treatment allocation ratio is 1 : 1. The planned treatment duration is $\tau_c = 1$ or 3 years for each subject, but subjects may discontinue the trial early with a $w_c = 25\%$ chance and the loss to follow-up is exponentially distributed. We also assess the performance of the proposed method at other parameter values ($\lambda_0 = 0.8$, $\kappa = 1.2$, $w_c = 0$).

We compare several sample size procedures for the NB regression. In [Zhu and Lakkis \(2014\)](#), three methods were proposed to evaluate the variance of the test statistic under H_0 . We evaluate only the approach recommended by the authors, in which the null variance is calculated based on the approximate restricted MLE. The sample size estimate by [Tang \(2015\)](#) method for the Wald test is also presented for the purpose of comparison. [Table 2](#) reports sample size estimates at the target power, and the power estimates at the sample size N_{new} determined by equation (9). The simulated power is evaluated based on 160,000 trials. There is more than 95% chance that the simulated power lies within $2\sqrt{0.8 * 0.2/160000} = 0.2\%$ and $2\sqrt{0.9 * 0.1/160000} = 0.15\%$ of the true power respectively when the target power is 80% and 90%. Because the estimated sample size is rounded up to the nearest integer, the nominal power by the proposed method at N_{new} is slightly larger than the target power. The proposed method yields the nominal power estimate that is generally within 1% of the simulated power, evidencing the accuracy of the proposed method.

Because the treatment effect is quite large ($\lambda_1/\lambda_0 = 0.4$), the variances of the score statistic under H_0 and H_1 are not close. Self and Mauritsen’s method (equation (10)) underestimates the required size while formula (11) overestimates the sample size. [Tang \(2017, 2018b\)](#) demonstrates that the method of [Zhu and Lakkis \(2014\)](#) underestimates the required size if the follow-up time varies across patients. [Table 2](#) indicates that Zhu-Lakkis’s formula still underestimates the sample size and overestimates the power even if all patients have equal follow-up time. At the target 90% power, the sample size estimates are quite close for the Wald and score tests. But at the target 80% power, the score test requires about 7.0% to 8.5% more subjects than the Wald test when $\lambda_0 = 1.1$, $\tau_c = 3$ and $w_c = 0$ or 25% in this example.

Example 2 We compare the proposed method, Self and Mauritsen’s procedure and [Zhu \(2017\)](#) approach for the sample size determination in NI trials. For the purpose of illustration, we set $\lambda_0 = 1.0$ or 1.5, $w_c = 0$ or 25%, $\kappa = 1$, $\lambda_1/\lambda_0 = 0.8$ or 1, and $M_0 = 1.25$. In practice, one typically assumes the true rate ratio is 1 or close to 1 in designing a NI trial. If the experimental treatment is truly more effective than the control treatment, but the treatment effect is relatively small (e.g. true rate ratio = 0.8), a NI trial may be chosen if it is infeasible to run a superiority trial that requires a much larger sample size. If the

NI test is significant, one may continue to conduct a superiority test to assess whether the experimental treatment is more effective than the control treatment. In this example, we focus on determining the sample size and power for the NI test. The simulated power is evaluated based on 160,000 trials. There is more than 95% chance that the simulated power lies within $2\sqrt{0.8 * 0.2/160000} = 0.2\%$ of the true power.

Table 3 reports sample size estimates at the target $P = 80\%$ and 90% power and $\alpha = 0.05$. Since the NI test is one-sided, the actual type I error rate is $\alpha/2 = 0.025$. Because the treatment effect is smaller in NI trials than in superiority trials, the differences in the sample size estimates from various methods reduce in NI trials, but the general pattern is similar to that in Example 1.

4 Sample size for logistic regression

Self and Mauritsen (1988) investigated the sample size estimation for comparing two binomial proportions ($g_i = 0$ or 1) using logistic regression while controlling for a categorical covariate z_i with $S = 2$ levels. We call z_i a stratum variable, and revisit the problem with $S \geq 2$ strata. Suppose for subjects in stratum s , y_i follows a Bernoulli distribution with the probability of success

$$\Pr(y_i = 1 | g_i, z_i = s) = \frac{\exp(\alpha_0 + \alpha_s + \beta g_i)}{1 + \exp(\alpha_0 + \alpha_s + \beta g_i)} = \frac{1}{1 + \exp(-\alpha_0 - \alpha_s - \beta g_i)}, \quad (21)$$

where $\exp(\alpha_0)$ is the odds at $g_i = 0$ in stratum 1, $\exp(\beta)$ is the odds ratio associated with the group status g_i among subjects from the same stratum, and $\exp(\alpha_s)$ is the odds ratio for subjects in stratum s relative to subjects with the same g_i from stratum 1 ($\alpha_1 = 0$).

Model (21) can be used to analyze data from both perspective clinical trials and retrospective case-control studies. The objectives are different, but the underlying statistical problems are similar in the two types of studies. Table 4 displays the data format for both studies. In a clinical trial, we compare the proportion of responders between two treatment groups, where x_{gs} is the number of responders among n_{gs} subjects assigned to treatment group g in stratum s . In the case-control study, the aim is to compare the proportion of

exposed between the case and control groups, where x_{gs} is the number of exposed subjects among n_{gs} case ($g = 1$) or control ($g = 0$) subjects in stratum s .

In fact, the score test for testing $H_0 : \beta = 0$ has explicit analytic expression

$$Z = \frac{\sum_{s=1}^S \frac{n_{s1}n_{s0}}{n_s} (\hat{p}_{s1} - \hat{p}_{s0})}{\sqrt{\sum_{s=1}^S \frac{n_{s1}n_{s0}}{n_s} \bar{p}_s (1 - \bar{p}_s)}}, \quad (22)$$

where $\hat{p}_{sg} = x_{sg}/n_{sg}$, $n_s = n_{s0} + n_{s1}$, and $\bar{p}_s = (x_{s0} + x_{s1})/n_s$. The power and sample size formulae in Section 2.3 can be used by setting

$$\begin{aligned} E_\beta &= \sum_{s=1}^S t_s \rho_s (1 - \rho_s) (p_{s1} - p_{s0}), \\ \sigma_0^2 &= \sum_{s=1}^S t_s \rho_s (1 - \rho_s) p_s^* (1 - p_s^*), \\ \sigma_1^2 &= \sum_{s=1}^S t_s \rho_s (1 - \rho_s) [(1 - \rho_s) p_{s1} (1 - p_{s1}) + \rho_s p_{s0} (1 - p_{s0})], \end{aligned} \quad (23)$$

where $p_{sg} = E(\hat{p}_{sg})$ is the true response rate, $n = \sum_{s=1}^S n_s$ is the total sample size, $t_s = \frac{n_s}{n}$ is the proportion of subjects contributed by stratum s , $\rho_s = \frac{n_{s1}}{n_s}$ is the proportion of subjects from group $g = 1$ in stratum s , and $p_s^* = \rho_s p_{s1} + (1 - \rho_s) p_{s0}$. The technical details are omitted here. We will extend the method to sample size determination for the stratified score tests in superiority, NI and equivalence trials on basis of the risk difference, relative risk or odds ratio effect measures in Tang (2019), and a general proof will be presented in that paper. The score statistic (22) is identical to Cochran (1954) statistic, and the power formula (8) is identical to that derived by Nam (1992) for Cochran's test although Nam (1992) considered only the case-control studies.

We conduct two simulation studies to compare several methods.

Example 3 Suppose there are two strata. Let $(\Pi_1, \Pi_2, \Pi_3, \Pi_4)$ denote respectively the proportion of subjects with $(g_i, z_i) = (0, 1), (0, 2), (1, 1)$ and $(1, 2)$. Thus $t_1 = \Pi_1 + \Pi_3$, $t_2 = \Pi_2 + \Pi_4$, $\rho_1 = \frac{\Pi_3}{t_1}$ and $\rho_2 = \frac{\Pi_4}{t_2}$. We set $(\Pi_1, \Pi_2, \Pi_3, \Pi_4) = (.25, .25, .25, .25)$ and $(.4, .1, .1, .4)$. The odds ratio associated with the stratum is $\exp(\alpha_1) = 2$, and the odds

ratio for the exposure is $\exp(\beta) = 2$ or 3 . The overall response rate in the study population

$$\bar{\mu} = \frac{\Pi_1}{1 + \exp(-\alpha_0)} + \frac{\Pi_2}{1 + \exp(-\alpha_0 - \alpha_1)} + \frac{\Pi_3}{1 + \exp(-\alpha_0 - \beta)} + \frac{\Pi_4}{1 + \exp(-\alpha_0 - \alpha_1 - \beta)}$$

is set to 0.15 and 0.5, which is used to derive α_0 . The set up is similar to that reported in Table 2 of [Self and Mauritsen \(1988\)](#).

Table 5 displays the power and sample size results at the target power 80%, 90% and 95%, and two-sided type I error 0.05. The analytic expression (10) gives the same sample size estimates as that reported in table 2 of [Self and Mauritsen \(1988\)](#) in all cases at $\bar{\mu} = 0.5$, but slightly larger estimates in all cases at $\bar{\mu} = 0.15$ possibly due to rounding errors. This verifies the validity of the power and sample size calculation based on the simpler equation (23) in the logsitic regression. The simulated power is estimated at the sample size N_{new} from the proposed method based on 10^6 simulated datasets. There is more than 95% chance that the simulated power lies within $2\sqrt{0.8 * 0.2/10^6} = 0.08\%$ of the true power.

All methods perform well possibly because the sample sizes are balanced overall between two groups ($\Pr(g = 1) = \Pr(g = 0) = 0.5$) although when $(\Pi_1, \Pi_2, \Pi_3, \Pi_4) = (.4, .1, .1, .4)$, the sample sizes are highly unbalanced between two groups within each stratum. We compare the methods by assessing how close the estimated nominal power is to the empirical power at a given sample size. There are more cases with $> 1\%$ difference between the nominal and simulated power estimates by formulae (10) and (11) than by formula (8). In nearly all cases at $(\Pi_1, \Pi_2, \Pi_3, \Pi_4) = (.4, .1, .1, .4)$, the nominal power by formula (8) is closer to the simulated power than that by equation (10).

dropout proportion	event rate	total sample size estimates							power (%) at N_{new}					
		w_c (%)	λ_0	κ	τ_c	N_{new}	N_{SM}	N_{s0}	ZL ^(a)	Wald ^(b)	SIM ^(c)	P_{new}	P_{SM}	P_{s0}
target power 80%														
0	1.1	0.9	3	58	38	68	51	54	80.85	80.29	93.83	73.59	84.74	
0	1.1	1.2	3	70	46	82	63	65	80.80	80.48	93.57	73.96	84.38	
0	0.8	0.9	3	65	44	76	58	61	80.91	80.10	92.87	73.96	84.52	
0	0.8	1.2	3	77	52	89	69	73	80.84	80.24	92.77	74.17	84.22	
0	1.1	0.9	1	96	72	107	86	94	81.05	80.22	89.94	75.71	84.20	
0	1.1	1.2	1	108	81	121	97	105	80.88	80.17	90.22	75.51	84.02	
0	0.8	0.9	1	117	93	128	105	116	81.15	80.17	88.48	76.38	83.95	
0	0.8	1.2	1	129	101	143	117	127	81.02	80.09	88.87	76.09	83.82	
25	1.1	0.9	3	64	42	74	54	59	81.07	80.60	93.42	74.21	86.36	
25	1.1	1.2	3	76	51	88	65	71	80.62	80.38	93.04	74.17	85.77	
25	0.8	0.9	3	72	50	83	61	68	80.93	80.20	92.33	74.39	85.92	
25	0.8	1.2	3	85	58	97	73	80	81.03	80.51	92.39	74.72	85.85	
25	1.1	0.9	1	108	83	120	94	105	81.12	80.26	89.43	76.03	85.22	
25	1.1	1.2	1	121	92	135	105	117	81.12	80.28	89.76	75.87	85.24	
25	0.8	0.9	1	132	106	144	116	131	81.10	80.11	87.95	76.56	84.73	
25	0.8	1.2	1	145	115	159	127	143	80.87	80.07	88.38	76.31	84.79	
target power 90%														
0	1.1	0.9	3	74	50	91	69	72	89.88	90.41	97.69	83.30	91.97	
0	1.1	1.2	3	89	61	109	84	87	89.75	90.37	97.52	83.50	91.65	
0	0.8	0.9	3	83	59	101	78	82	89.90	90.16	97.20	83.65	91.81	
0	0.8	1.2	3	98	70	119	93	97	89.60	90.12	97.11	83.72	91.54	
0	1.1	0.9	1	124	97	143	116	125	90.25	90.17	95.73	85.53	91.79	
0	1.1	1.2	1	139	108	162	131	140	89.93	90.07	95.83	85.24	91.60	
0	0.8	0.9	1	152	124	172	143	155	90.50	90.13	94.96	86.28	91.72	
0	0.8	1.2	1	167	135	191	158	170	90.24	90.02	95.13	85.92	91.57	
25	1.1	0.9	3	81	56	99	73	79	89.88	90.26	97.39	83.54	92.91	
25	1.1	1.2	3	97	68	118	88	95	89.80	90.34	97.29	83.82	92.72	
25	0.8	0.9	3	92	66	111	83	91	89.99	90.16	96.92	84.05	92.80	
25	0.8	1.2	3	108	78	130	98	107	89.73	90.18	96.88	84.13	92.64	
25	1.1	0.9	1	139	111	160	127	141	90.27	90.02	95.36	85.68	92.41	
25	1.1	1.2	1	156	123	180	142	157	90.15	90.13	95.59	85.61	92.49	
25	0.8	0.9	1	172	142	193	157	175	90.48	90.13	94.69	86.53	92.33	
25	0.8	1.2	1	189	154	213	172	192	90.24	90.17	94.96	86.34	92.40	

Table 2: Estimated sample size at the target 90% power and estimated power for the score test from NB regression in superiority trials

^(a) Method 3 of [Zhu and Lakkis \(2014\)](#). It estimates the null variance of the test statistic based on the approximate restricted MLE.

^(b) Sample size estimate by [Tang \(2015\)](#) method for Wald test is displayed for comparison

^(c) Simulated power (SIM) are evaluated at N_{new} based on 160,000 simulated datasets.

dropout proportion w_c (%)	event rate λ_0	true rate ratio	κ	total sample size estimates						power (%) at N_{new}				
				N_{new}	N_{SM}	N_{s0}	Zhu ^(a)	Wald ^(b)	SIM ^(c)	nominal power				
										P_{new}	P_{SM}	P_{s0}	Zhu ^(a)	
0	1.0	0.8	1	337	313	348	334	335	79.93	80.02	82.92	78.76	80.41	
0	1.5	0.8	1	278	253	290	275	276	79.88	80.02	83.63	78.45	80.47	
25	1.0	0.8	1	377	351	388	361	375	80.15	80.10	82.77	78.93	81.76	
25	1.5	0.8	1	308	282	319	293	306	80.09	80.09	83.46	78.62	82.00	
0	1.0	1.0	1	1264	1244	1272	1264	1262	80.01	80.02	80.62	79.76	80.01	
0	1.5	1.0	1	1053	1031	1063	1053	1051	80.07	80.01	80.84	79.65	80.02	
25	1.0	1.0	1	1407	1388	1416	1360	1405	79.85	80.00	80.55	79.77	81.33	
25	1.5	1.0	1	1161	1139	1171	1117	1160	79.95	80.01	80.78	79.68	81.53	

Table 3: Estimated sample size at the target 80% power and estimated power for the score test from NB regression in NI trials

^(a) Method 3 of [Zhu \(2017\)](#). It estimates the null variance of the test statistic based on the approximate restricted MLE.

^(b) Sample size estimate by [Tang \(2015\)](#) method for Wald test is displayed for comparison

^(c) Simulated power (SIM) are evaluated at N_{new} based on 160,000 simulated datasets.

Event	Clinical trials					exposure status	Case-control study				
	$z = 1$...	$z = S$			$z = 1$...	$z = S$	
	placebo $g = 0$	active $g = 1$		placebo $g = 0$	active $g = 1$		control $g = 0$	case $g = 1$		control $g = 0$	case $g = 1$
Yes	x_{10}	x_{11}	...	x_{S0}	x_{S1}	exposed	x_{10}	x_{11}	...	x_{S0}	x_{S1}
No	$n_{10} - x_{10}$	$n_{11} - x_{11}$...	$n_{S0} - x_{S0}$	$n_{S1} - x_{S1}$	No	$n_{10} - x_{10}$	$n_{11} - x_{11}$...	$n_{S0} - x_{S0}$	$n_{S1} - x_{S1}$
Sum	n_{10}	n_{11}	...	n_{S0}	n_{S1}	Sum	n_{10}	n_{11}	...	n_{S0}	n_{S1}

Table 4: Binary outcomes from stratified clinical trials and case-control studies

		$(\Pi_1, \Pi_2, \Pi_3, \Pi_4) = (.25, .25, .25, .25)$										$(\Pi_1, \Pi_2, \Pi_3, \Pi_4) = (.4, .1, .1, .4)$									
$\bar{\mu}$	$\exp(\beta)$	target power (%)	α_0	estimated size			nominal power (%)			α_0	estimated size			nominal power (%)							
				N_{new}	N_{sw}	N_{s0}	SIM	\bar{P}_{new}	\bar{P}_{SM}		\bar{P}_{s0}	N_{new}	N_{sw}	N_{s0}	SIM	\bar{P}_{new}	\bar{P}_{SM}	\bar{P}_{s0}			
.15	2	80	-2.5102	543	537	546	80.58	80.02	80.44	79.84	-2.5597	882	853	894	80.51	80.04	81.32	79.49			
		90	-2.5102	726	719	730	90.37	90.02	90.28	89.84	-2.5597	1175	1142	1197	90.25	90.02	90.81	89.49			
		95	-2.5102	897	890	903	95.25	95.01	95.16	94.88	-2.5597	1449	1412	1480	95.13	95.01	95.47	94.61			
	3	80	-2.7737	231	225	233	81.55	80.13	81.12	79.70	-2.8507	382	360	392	81.24	80.05	82.32	79.07			
		90	-2.7737	308	301	312	90.98	90.08	90.69	89.67	-2.8507	507	482	524	90.59	90.02	91.41	89.06			
		95	-2.7737	380	372	386	95.61	95.05	95.40	94.74	-2.8507	624	596	648	95.42	95.02	95.82	94.28			
.50	2	80	-0.6931	273	267	275	79.88	80.10	80.88	79.75	-0.6931	417	432	411	80.05	80.04	78.63	80.65			
		90	-0.6931	364	358	368	89.88	90.03	90.52	89.71	-0.6931	561	578	550	90.21	90.03	89.14	90.60			
		95	-0.6931	449	442	455	95.13	95.01	95.29	94.76	-0.6931	696	715	679	95.00	95.02	94.49	95.45			
	3	80	-0.8959	111	105	113	81.76	80.28	82.22	79.43	-0.8959	166	173	163	80.15	80.10	78.42	80.82			
		90	-0.8959	147	141	151	89.63	90.09	91.29	89.27	-0.8959	223	232	218	90.21	90.01	88.94	90.68			
		95	-0.8959	181	174	187	94.95	95.06	95.75	94.43	-0.8959	277	286	270	94.94	95.02	94.39	95.52			

Table 5: Power and sample size estimate for the score test from logistic regression with equal group sample sizes
[1] Simulated power (SIM) are evaluated at N_{new} based on 1000,000 simulated datasets.

Example 4 [Self et al. \(1992\)](#) observed that the [Self and Mauritsen \(1988\)](#) method degrades when the sample sizes are highly unbalanced between two groups. In this simulation, the set up is similar to that reported in Table 1 of [Self et al. \(1992\)](#). We set $\pi = \Pr(g = 1) = 0.05, 0.5, 0.75$, $\Pr(Z = 2|g = 1) = 0.8$, and $\Pr(Z = 2|g = 0) = 0.2$. Thus $(\Pi_1, \Pi_2, \Pi_3, \Pi_4) = (0.8(1 - \pi), 0.2(1 - \pi), 0.2\pi, 0.8\pi)$. Note that $\pi = 0.5$ (0.75) corresponds to the 1 : 1 (3 : 1) treatment allocation ratio, which is commonly used in clinical trials. The scenario $\pi = 0.05$ may arise in case-control studies or in genetic studies when a small proportion of subjects carry the risk genotypes ([Tang, 2011](#)). The true odds ratio is $\exp(\alpha_1) = 2$ for stratum and $\exp(\beta) = 2$ for exposure. The overall response rate in the study population

$$\bar{\mu} = \frac{\Pi_1}{1 + \exp(-\alpha_0)} + \frac{\Pi_2}{1 + \exp(-\alpha_0 - \alpha_1)} + \frac{\Pi_3}{1 + \exp(-\alpha_0 - \beta)} + \frac{\Pi_4}{1 + \exp(-\alpha_0 - \alpha_1 - \beta)}$$

is set to 0.02 and 0.15. Because the sample size estimates vary greatly by methods, we evaluate the nominal power and empirical power based on 10^6 simulations at both the sample sizes from the proposed and [Self and Mauritsen \(1988\)](#) methods. We repeat the simulation for unstratified score tests without adjustment for the stratum effect when there is no confounding effect ($\alpha_1 = 0$), where α_0 is the solution to

$$\bar{\mu} = \frac{\pi}{1 + \exp(-\alpha_0 - \beta)} + \frac{1 - \pi}{1 + \exp(-\alpha_0)}.$$

Table 6 displays the power and sample size results. The nominal power by formula (8) is very close to the simulated power, but formulae (10) and (11) may produce very poor power estimates which can deviate from the simulated power by 16% in some cases.

5 Discussion

We propose a modification of the [Self and Mauritsen \(1988\)](#) method for sample size calculation for score tests from GLMs, and extend it to the NI trials. The modification takes into account of the fact that the variance of the score statistic differs under H_0 and H_1 . The proposed method is also suitable for other regression models. For example, the binary outcome is often analyzed by the logistic regression on basis of the odds ratio between two

π	$\bar{\mu}$	α_0	target	estimated size			power (%) at N_{sw}				power (%) at N_{new}			
			power(%)	N_{new}	N_{sw}	N_{s0}	SIM	P_{new}	P_{SM}	P_{s0}	SIM	P_{new}	P_{SM}	P_{s0}
No confounding or stratum effect: $p(y = 1 z, g) = \frac{1}{1+\exp[-\alpha_0-g\log(2)]}$														
.05	.02	-3.9398	80	11661	17232	9601	91.07	90.97	80.00	96.35	80.08	80.00	63.48	87.03
			90	16537	23069	12853	96.27	96.23	90.00	99.14	90.06	90.00	78.36	95.70
	.15	-1.7776	80	2035	2626	1805	88.37	88.04	80.00	92.22	80.02	80.00	69.37	84.51
			90	2826	3516	2416	94.99	94.71	90.01	97.45	90.27	90.00	82.80	93.90
.50	.02	-4.2951	80	3587	3581	3589	80.63	79.95	80.01	79.92	80.69	80.01	80.07	79.99
			90	4800	4794	4804	90.55	89.97	90.00	89.94	90.59	90.00	90.04	89.98
	.15	-2.1230	80	536	531	539	80.48	79.64	80.05	79.47	80.37	80.01	80.41	79.84
			90	717	711	721	90.18	89.78	90.04	89.62	90.42	90.03	90.28	89.86
.75	.02	-4.4502	80	5879	4651	6451	69.37	68.91	80.00	66.24	80.73	80.00	88.30	76.26
			90	7636	6226	8636	83.20	82.47	90.00	78.59	90.46	90.00	94.84	86.17
	.15	-2.2845	80	840	697	906	72.33	71.50	80.04	69.08	80.52	80.02	86.81	76.99
			90	1097	933	1213	84.85	84.33	90.03	81.17	90.24	90.00	94.02	86.95
Confounding: $p(y = 1 z, g) = \frac{1}{1+\exp[-\alpha_0-z\log(2)-g\log(2)]}$														
.05	.02	-4.1643	80	9752	13078	8473	89.38	88.95	80.00	93.58	80.43	80.00	67.70	85.21
			90	13621	17507	11343	95.48	95.19	90.00	98.06	90.41	90.00	81.57	94.43
	.15	-1.9777	80	1943	2269	1811	85.58	85.33	80.01	88.02	80.30	80.00	73.66	82.69
			90	2659	3037	2425	93.54	93.19	90.00	95.24	90.39	90.01	85.84	92.43
.50	.02	-4.7609	80	6096	5596	6317	76.89	76.40	80.00	75.08	80.46	80.00	83.25	78.59
			90	8068	7492	8456	88.09	87.68	90.00	86.24	90.37	90.00	91.98	88.62
	.15	-2.5597	80	882	853	894	79.37	78.69	80.03	78.15	80.69	80.04	81.32	79.49
			90	1175	1142	1197	89.59	89.18	90.02	88.63	90.32	90.02	90.81	89.49
.75	.02	-4.9868	80	10398	8795	11127	72.84	72.48	80.00	70.22	80.46	80.00	86.14	77.29
			90	13618	11773	14896	85.45	85.01	90.00	82.17	90.42	90.00	93.65	87.27
	.15	-2.8044	80	1419	1271	1486	76.01	75.27	80.03	73.62	80.46	80.00	84.17	78.18
			90	1872	1701	1989	87.46	86.92	90.01	85.04	90.35	90.00	92.52	88.20

Table 6: Power and sample size estimate for the score test from logistic regression with unequal group sample sizes

[1] Simulated power (SIM) are evaluated at N_{new} based on 1000,000 simulated datasets.

groups. Now suppose the parameter of interest is the relative risk instead of the odds ratio. The method is still suitable if the model is reparametrized in terms of the response rate in the control group and the relative risk parameter (Tang, 2019).

The proposed method shows a marked improvement over the Self and Mauritsen (1988) formula in logistic and NB regressions when either the treatment effect is large or sample sizes are unbalanced in the two groups. In these situations, the Self and Mauritsen (1988) method degrades because the variance of the score statistic can be quite different under H_0 and H_1 . As illustrated in Section 3, the approaches of Zhu and Lakkis (2014) and Zhu (2017) for NB regression tend to underestimate the size 1) when there is a large variation

in the patients' follow-up time, and/or 2) when there is a large treatment effect.

The sample size calculation for the score test requires the construction and analysis of an exemplary dataset if the model is complex, and there is no analytic solution for the restricted MLE under the null hypothesis. The main computation time lies in the analysis of the exemplary data, and this can usually be done within few minutes. It is much quicker than the simulation method, which requires the generation and analysis of at least thousands of datasets in order to get a quite precise power estimate at a given sample size. As evidenced by the results in Tables 1 and 2, the sample size procedure shall be consistent with the test used for the analysis (Zhu and Lakkis, 2014). Otherwise, the study may be either underpowered or overpowered. We recommend using the proposed procedure (or a simplified version if it exists) to determine the sample size if one plans to analyze the trial using the score test.

A future research direction is to extend the exemplary dataset approach to the Wald test and score test (Liu and Liang, 1997) from the generalized estimating equations (GEE) in the analysis of repeated measurements. The sample size calculation is complicated even for the Wald test in GEEs because there are missing outcomes, and the working correlation structure may be different from the true correlation structure. Even if the analytic formula exists by using the independent or true correlation structure, the calculation can still be complex to account for missing data. In the exemplary dataset approach, one can get the noncentrality parameter for the Wald test directly through the analysis of the exemplary data. The generation of the exemplary data also provides an opportunity to verify whether the sample size assumption is correct for correlated outcomes.

References

- Aban, I. B., G. R. Cutter, and N. Mavinga (2009). Inferences and power analysis concerning two negative binomial distributions with an application to MRI lesion counts data. *Computational Statistics & Data Analysis* 53, 820 – 33.
- Cochran, W. G. (1954). Some methods for strengthening the common chi-square tests. *Biometrics* 10, 417 – 51.

- Cox, D. R. and D. V. Hinkley (1974). *Theoretical Statistics*. Chapman & Hall, London.
- Farrington, C. P. and G. Manning (1990). Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. *Statistics in Medicine* 9, 1447 – 54.
- Laud, P. J. and A. Dane (2014). Confidence intervals for the difference between independent binomial proportions: comparison using a graphical approach and moving averages. *Pharmaceutical Statistics* 13, 294 – 308.
- Lawless, J. F. (1987). Negative binomial and mixed Poisson regression. *The Canadian Journal of Statistics* 15, 209–25.
- Liu, G. and K. Y. Liang (1997). Sample size calculations for studies with correlated observations. *Biometrics* 53, 937 – 47.
- Lyles, R. H., H. Lin, and J. M. Williamson (2007). A practical approach to computing power for generalized linear models with nominal, count, or ordinal responses. *Statistics in Medicine* 26, 1632 – 48.
- Matsui, S. (2005). Sample size calculations for comparative clinical trials with over-dispersed Poisson process data. *Statistics in Medicine* 24, 1339 – 56.
- McCullagh, P. and J. A. Nelder (1989). *Generalized Linear Models, 2nd Edition*. Chapman & Hall, London.
- Nam, J. (1992). Sample size determination for case-control studies and the comparison of stratified and unstratified analyses. *Biometrics* 48, 389 – 95.
- Nelder, J. A. and R. W. M. Wedderburn (1972). Generalized linear models. *Journal of the Royal Statistical Society, Series A* 135, 370 – 84.
- Nemes, S., J. M. Jonasson, A. Genell, and G. Steineck (2009). Bias in odds ratios by logistic regression modelling and sample size. *BMC Medical Research Methodology* 9, 56.
- Self, S. G. and R. H. Mauritsen (1988). Power/sample size calculations for generalized linear models. *Biometrics* 44, 79 – 86.

- Self, S. G., R. H. Mauritsen, and J. O’Hara (1992). Power calculations for likelihood ratio tests in generalized linear models. *Biometrics* 48, 31 – 9.
- Tang, Y. (2011). Size and power estimation for the Wilcoxon-Mann-Whitney test for ordered categorical data. *Statistics in Medicine* 30, 3461 – 70.
- Tang, Y. (2015). Sample size estimation for negative binomial regression comparing rates of recurrent events with unequal follow-up time. *Journal of Biopharmaceutical Statistics* 25, 1100 – 13.
- Tang, Y. (2017). Negative binomial regression: Sample size with unequal follow-up times. In *Encyclopedia of Biopharmaceutical Statistics, Third Edition* DOI: 10.1081/E-EBS3-140000049. Taylor and Francis: New York.
- Tang, Y. (2018a). Algorithms for imputing partially observed recurrent events with applications to multiple imputation in pattern mixture models. *Journal of Biopharmaceutical Statistics* 28, 518–33.
- Tang, Y. (2018b). Sample size for comparing negative binomial rates in noninferiority trials with unequal follow-up times. *Journal of Biopharmaceutical Statistics* 28, 475 – 91.
- Tang, Y. (2019). Score confidence intervals and sample sizes for stratified comparisons of binomial proportions. *submitted*.
- Whitehead, J. (1993). Sample size calculations for ordered categorical data. *Statistics in Medicine* 12, 2257 – 71.
- Xing, G., C.-Y. Lin, S. P. Wooding, and C. Xing (2012). Blindly using Wald’s test can miss rare disease-causal variants in case-control association studies. *Annals of Human Genetics* 76, 168 – 77.
- Zhao, Y. D., D. Rahardja, and Y. Qu (2008). Sample size calculation for the Wilcoxon-Mann-Whitney test adjusting for ties. *Statistics in Medicine* 27, 462 – 68.
- Zhu, H. (2017). Sample size calculation for comparing two poisson or negative binomial rates in non-inferiority or equivalence trials. *Statistics in Biopharmaceutical Research* 9, 107 – 15.

Zhu, H. and H. Lakkis (2014). Sample size calculation for comparing two negative binomial rates. *Statistics in medicine* 33, 376–87.